EUVIMEDEUVIMED entdecken
Vergleichsstudie

Control of myopia progression by low‐dose atropine (0.01%, 0.025% and 0.05%), defocus incorporated multiple segments/highly aspherical lenslets spectacles, and combined therapy in European children: A 3‐year retrospective study

Manon Grégoire, Léa Dormegny, David Gaucher, Lauriana Solecki, Tristan Bourcier, Arnaud Sauer

Optometry and Vision Science · 2026

DOI: 10.1002/ovs2.70007 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Optometry and Vision Science, 2026. Verfasst von Manon Grégoire und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Strasbourg University Hospital, Strasbourg, France. Hauptthemen laut MEDLINE: Atropine, Eyeglasses, Refraction, Ocular, Myopia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: PHRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Myopia control is crucial for pediatric eye care professionals. Although various treatments exist, their comparative efficacy, particularly in European populations, remains unclear. In real‐life conditions, this study aimed to compare different strategies to slow myopia progression.

Methods

This retrospective, nonrandomized study evaluated the efficacy of 0.01%, 0.025%, and 0.05% atropine, defocus incorporated multiple segments/highly aspherical lenslets (DIMS/HAL) spectacles, combined atropine and DIMS/HAL, and single vision spectacles in 288 European children (aged 5–12 years) with myopia progression (≥0.75 D in the past 12 months). Primary outcomes were changes in spherical equivalent refraction (SER) and axial length measured every 6 months for 3 years.

Results

The mean cumulative 3‐year SER progressions were −0.75 ± 0.49, −0.92 ± 0.52, and −1.31 ± 0.75 D for the 0.05%, 0.025%, and 0.01% atropine groups, respectively, −1.31 ± 0.76 D for the DIMS/HAL group, and −1.11 ± 0.65 D for the 0.01% atropine + DIMS/HAL group, showing better myopia progression control compared to those of the control group (−2.14 ± 0.72 D). Atropine exhibited a dose‐dependent effect, with 0.05% atropine achieving the greatest reduction in myopia progression and axial elongation.

Conclusions

This study demonstrates the efficacy of low‐dose atropine and DIMS/HAL spectacles in slowing myopia progression in European children. The 0.05% atropine exhibited the most pronounced myopia control effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtropineEyeglassesRefraction, OcularMyopiaHumansRetrospective StudiesChildChild, PreschoolDisease ProgressionMaleMydriaticsFemaleFollow-Up StudiesOphthalmic SolutionsDose-Response Relationship, DrugEuropeTreatment OutcomeTime Factors

Substanzen

AtropineMydriaticsOphthalmic Solutions

Autor:innen und Institutionen

  • Department of Ophthalmology, Strasbourg University Hospital, Strasbourg, France.

Förderung

  • PHRC

Zitieren

APA

Grégoire, M., Dormegny, L., Gaucher, D., Solecki, L., Bourcier, T., & Sauer, A. (2026). Control of myopia progression by low‐dose atropine (0.01%, 0.025% and 0.05%), defocus incorporated multiple segments/highly aspherical lenslets spectacles, and combined therapy in European children: A 3‐year retrospective study. Optometry and Vision Science. https://doi.org/10.1002/ovs2.70007

Vancouver

Grégoire M, Dormegny L, Gaucher D, Solecki L, Bourcier T, Sauer A. Control of myopia progression by low‐dose atropine (0.01%, 0.025% and 0.05%), defocus incorporated multiple segments/highly aspherical lenslets spectacles, and combined therapy in European children: A 3‐year retrospective study. Optometry and Vision Science. 2026. doi:10.1002/ovs2.70007

BibTeX
@article{Grgoire2026,
  author = {Grégoire, Manon and Dormegny, Léa and Gaucher, David and Solecki, Lauriana and Bourcier, Tristan and Sauer, Arnaud},
  title = {Control of myopia progression by low‐dose atropine (0.01%, 0.025% and 0.05%), defocus incorporated multiple segments/highly aspherical lenslets spectacles, and combined therapy in European children: A 3‐year retrospective study},
  journal = {Optometry and Vision Science},
  year = {2026},
  doi = {10.1002/ovs2.70007}
}
Kostenlos starten →